Abstract: The present invention permits identification of biological materials following recovery of DNA using standard techniques by comparing a mathematical characterization of the unknown sequence with the mathematical characterization of DNA sequences of known genera and species. The clinical identification of infectious organisms is required for accurate diagnosis and selection of antimicrobial therapeutics. The invention allows an ab initio approach with the potential for rapid identification of biological materials of unknown origin. The approach provides for identification and classification of emergent or new organisms without previous phenotypic identification. The technique may also be used in monitoring situations where the need exists for classification of material into broad categories of bacteria which could have an immediate impact on bio-terrorism prevention.

Abstract: Materials and methods are provided which rapidly and specifically different between pathogenic and non-pathogenic Aspergillus species in a biological sample.

Abstract: Methods are provided for generating, building, updating, and searching a custom database of biological sequences. Methods for differentiating between M. tuberculosis and M. bovis and detecting pyrazinamide (PZA) resistance are also provided.

Abstract: The present invention relates to members of the cyclic AMP responsive element binding protein/activating transcription factor 1 (CREB/ATF1) family of transcription factors. An embodiment of this invention constitutes an inhibitory agent (e.g., an antibody, small molecule or polypeptide) which binds to a fragment, spanning from about position 167 to about 181 of the amino acid sequence of the ATF1 protein bound to the target gene, with sufficient binding affinity to cause disassociation of ATF1 from the DNA of the target gene and/or prevent ATF1 from binding thereto through a currently unknown mechanism. As a result, transcription is prevented or, at least, inhibited, resulting in events of consequence to a virus or cell.

Abstract: The present invention relates to members of the cyclic AMP responsive element binding protein/activating transcription factor 1 (CREB/ATF1) family of transcription factors. An embodiment of this invention constitutes an inhibitory agent (e.g., an antibody, small molecule or polypeptide) which binds to a fragment, spanning from about position 167 to about 181 of the amino acid sequence of the ATF1 protein bound to the target gene, with sufficient binding affinity to cause disassociation of ATF1 from the DNA of the target gene and/or prevent ATF1 from binding thereto through a currently unknown mechanism. As a result, transcription is prevented or, at least, inhibited, resulting in events of consequence to a virus or cell.